tbuckley/cabot-search huggingface dataset:
Clinical Features of Pheochromocytoma.
Authors: R. W. Gifford
Journal: Annals of Internal Medicine (1962)

s1 April 1962Clinical Features of Pheochromocytoma.R. W. Gifford Jr., M.D. (Assoc.), W. F. Kvale, M.D., F.A.C.P., F. T. Maher, M.D., G. M. Roth, Ph.D., J. T. Priestley, M.D.R. W. Gifford Jr., M.D. (Assoc.)Search for more papers by this author, W. F. Kvale, M.D., F.A.C.P.Search for more papers by this author, F. T. Maher, M.D.Search for more papers by this author, G. M. Roth, Ph.D.Search for more papers by this author, J. T. Priestley, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-56-4-667_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA review of 71 cases of pheochromocytoma, diagnosed antemortem at the Mayo Clinic, revealed that the diagnosis was strongly suspected clinically before any confirmatory tests were performed in 65 cases. Salient features in the history included headache (83%), diaphoresis (74%), palpitations (65%), pallor (46%), nervousness (46%), and tremulousness (41%). These symptoms frequently occurred paroxysmally even though hypertension was sustained. Hypertension was paroxysmal in 35 cases, persistent in 35, and absent in one case in which the only symptom was profuse, persistent perspiration. Of 35 patients with paroxysmal hypertension, 17 were men and five of these were physicians! Of 36 patients... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, Minn. (CS) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPheochromocytoma 1 April 1962Volume 56, Issue 4Page: 667-667KeywordsAnxietyHeadachesHypertensionPheochromocytomaSweat Issue Published: 1 April 1962 PDF downloadLoading ...
Myocardial protection via coronary sinus interventions: superior effects of arterialization compared with intermittent occlusion.
Authors: A Zalewski, S Goldberg, S Slysh, P R Maroko
Journal: Circulation (1985)

It has been reported that infarct size can be reduced by several interventions, by which arterial blood is delivered retrogradely to the ischemic myocardium through the cardiac veins or alternatively the cardiac venous system is intermittently occluded. Accordingly, we studied several modalities of myocardial protection that used the cardiac venous system and compared them by means of a quantitative technique for measuring infarct size. Thus 73 anesthetized dogs with coronary arterial occlusion were randomized into the following groups: group I (n = 9), 6 hr of occlusion without any intervention; group II (n = 11), venovenous shunt (60 ml/min) to the great cardiac vein; group III (n = 11), arteriovenous shunt to the anterior interventricular vein; group IV (n = 12), high flow arteriovenous shunt to the anterior interventricular vein (60 ml/min); group V (n = 11), arteriovenous shunt to the great cardiac vein (60 ml/min); group VI (n = 10), arteriovenous shunt to the great cardiac vein (60 ml/min) combined with diastolic occlusion of the great cardiac vein; group VII (n = 9), intermittent pressure-controlled occlusion of the great cardiac vein without arterialization. The arteriovenous shunt (groups III to VI) or venovenous shunt (group II) was done by selective catheterization of the anterior interventricular vein or the great cardiac vein, advancing a catheter from the jugular vein through the right atrium and coronary sinus under fluoroscopic control. This catheter was then connected to a cannula located either in the carotid artery (groups III to VI) or in the right atrium (group II). One minute after occlusion, 99mTc-labeled albumin microspheres (8 mCi) were injected into the left atrium for the subsequent assessment of the hypoperfused zone, which is the area at risk for infarction.(ABSTRACT TRUNCATED AT 250 WORDS)
Genomic Engineering and the Future of Medicine
Authors: Jennifer A. Doudna
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation
Authors: I. V. F. van den Broek, J. E. A. M. van Bergen, E. E. H. G. Brouwers, J. S. A. Fennema, H. M. Gotz, C. J. P. A. Hoebe, R. H. Koekenbier, M. Kretzschmar, E. A. B. Over, B. V. Schmid, L. L. Pars, S. M. van Ravesteijn, M. A. B. van der Sande, G. A. de Wit, N. Low, E. L. M. Op de Coul
Journal: BMJ (2012)

<b>Objective</b> To evaluate the effectiveness of register based, yearly chlamydia screening. <b>Design</b> Controlled trial with randomised stepped wedge implementation in three blocks. <b>Setting</b> Three regions of the Netherlands: Amsterdam, Rotterdam, and South Limburg. <b>Participants</b> 317 304 women and men aged 16-29 years listed on municipal registers at start of trial. <b>Intervention</b> From March 2008 to February 2011, the Chlamydia Screening Implementation programme offered yearly chlamydia screening tests. Postal invitations asked people to use an internet site to request a kit for self collection of samples, which would then be sent to regional laboratories for testing. Treatment and partner notification were done by the general practitioner or at a sexually transmitted infection clinic. <b>Main outcome measures</b> Primary outcomes were the percentage of chlamydia tests positive (positivity), percentage of invitees returning a specimen (uptake), and estimated chlamydia prevalence. Secondary outcomes were positivity according to sex, age, region, and sociodemographic factors; adherence to screening invitations; and incidence of self reported pelvic inflammatory disease. <b>Results</b> The participation rate was 16.1% (43 358/269 273) after the first invitation, 10.8% after the second, and 9.5% after the third, compared with 13.0% (6223/48 031) in the control block invited at the end of round two of the intervention. Chlamydia positivity in the intervention blocks at the first invitation was the same as in the control block (4.3%) and 0.2% lower at the third invitation (odds ratio 0.96 (95% confidence interval 0.83 to 1.10)). No substantial decreases in positivity were seen after three screening rounds in any region or sociodemographic group. Among the people who participated three times (2.8% of all invitees), positivity fell from 5.9% to 2.9% (odds ratio 0.49 (0.47 to 0.50)). <b>Conclusions</b> There was no statistical evidence of an impact on chlamydia positivity rates or estimated population prevalence from the Chlamydia Screening Implementation programme after three years at the participation levels obtained. The current evidence does not support a national roll out of this register based chlamydia screening programme. <b>Trial registration</b> NTR 3071 (Netherlands Trial Register, www.trialregister.nl).
EFFECTS OF SILDENAFIL ON TISSUE PERFUSION AND PROINFLAMMATORY MOLECULES EXPRESSION IN A MURINE MODEL OF LIMB ISCHEMIA AND ATHEROSCLEROSIS
Authors: Aggeliki Valatsou, Dimitris Tousoulis, Alexandros Briasoulis, Georgia Vogiatzi, Charalambos Antoniades, Nikolaos Papageorgiou, Nikolaos Memos, Agapi Kataki, Alkistis Pantopoulou, Gerasimos Siasos, Despoina Perrea, Christodoulos Stefanadis
Journal: Journal of the American College of Cardiology (2011)
VAGINAL HYSTERECTOMY, A REVIEW OF SIXTY-SIX CONSECUTIVE CASES.
Authors: CHARLES GILBERT DAVIS
Journal: JAMA (1897)

Whatever adds to the health of woman tends directly to increase the happiness of the human race. On her physical condition hangs the destiny of nations. The truthfulness of this assertion is instinctively recognized by the medical world. Hence, volumes have been written, and a controversial warfare has been waged for centuries in an endeavor to elucidate her diseases and relieve her suffering. So bitter have been these conflicts in regard to the pathology of her ailments and their treatment, that the pelvic cavity may well be called the battle-ground of medical science. Every generation, every decade, sees new triumphs in the direction of truth. The last quarter of a century has witnessed a revolution in the surgery relating to the pelvic region. While general surgical methods have made a very decided advance, it must be conceded that some of the greatest triumphs have been achieved by improved operative measures
Flexible Sensors for Chronic Wound Management
Authors: Manuel Ochoa, Rahim Rahimi, Babak Ziaie
Journal: IEEE Reviews in Biomedical Engineering (2014)

Chronic nonhealing wounds are a major source of morbidity and mortality in bed-ridden and diabetic patients. Monitoring of physical and chemical parameters important in wound healing and remodeling process can be of immense benefit for optimum management of such lesions. Low-cost flexible polymeric and paper-based substrates are attractive platforms for fabrication of such sensors. In this review, we discuss recent advances in flexible physiochemical sensors for chronic wound monitoring. After a brief introduction to wound healing process and commercial wound dressings, we describe various flexible biocompatible substrates that can be used as the base platform for integration of wound monitoring sensors. We will then discuss several fabrication methods that can be utilized to integrate physical and chemical sensors onto such substrates. Finally, we will present physical and chemical sensors developed for monitoring wound microenvironment and outline future development venues.
Brush Border Disaccharidases in Dog Kidney and Their Spatial Relationship to Glucose Transport Receptors
Authors: Melvin Silverman
Journal: Journal of Clinical Investigation (1973)

The localization of disaccharidases in kidney has been studied by means of the multiple indicator dilution technique. A pulse injection of a solution containing Evans blue dye (plasma marker), creatinine (extracellular marker), and a (14)C-labeled disaccharide (lactose, sucrose, maltose, and alphaalpha-trehalose), is made into the renal artery of an anesthetized dog, and the outflow curves are monitored simultaneously from renal venous and urine effluents. Lactose and sucrose have an extracellular distribution. Trehalose and maltose remain extracellular from the postglomerular circulation. About 75% of filtered tracer maltose or trehalose is extracted by the luminal surface of the nephron. Thin-layer chromatography of urine samples shows that all of the excreted (14)C radiolabel is in the form of the injected disaccharide. Following the administration of phlorizin, all of the filtered radioactivity is recoverable in the urine, but chromatography of the urine samples now reveals that there is a significant excretion of [(14)C]glucose, approximating the amount previously extracted under control conditions (in the absence of phlorizin). It has been verified that no hydrolysis of maltose or trehalose to their constituent glucose subunits occurred during the transit of tracer between the point of injection (renal artery), and the point of filtration (glomerular basement membrane). Similarly, after addition of [(14)C]disaccharides to fresh urine there is no chromatographically recoverable [(14)C]glucose. It is concluded that there exist alpha-glucosidases with maltase and trehalase activity along the brush border of the proximal tubule and that these disaccharidases are located spatially superficial to the glucose transport receptors.
Unexplained Postoperative Fever
Authors: Michael H. M. Dykes
Journal: JAMA (1971)

This study of consecutive patients reveals that, during the first postoperative week, 55% of temperature elevations above 98.6 F (37 C) are unexplained. Further, only one patient of the 163 who had temperatures recorded for at least three postoperative days failed to demonstrate a temperature elevation. The mean temperatures of four groups of 20 consecutive patients who demonstrated unexplained elevations after four operations fell steadily from between 99.5 F (37.5 C) and 100.4 F (38 C) on the first postoperative day to between 98.6 F and 99.1 F (37.3 C) on the seventh. The maximum elevation was above 99.9 F (37.7 C) in 48 instances. Thirty-two patients who received halothane demonstrated a similar pattern to the 48 who did not. These data do not support the hypothesis that "unexplained postoperative fever" alone, following a prior administration of halothane, necessarily indicates that the patient has become sensitized to the drug.
THE PATHOLOGICAL EFFECTS UPON RATS OF EXCESS IRRADIATED ERGOSTEROL 1
Authors: Alfred T. Shohl, Harry Goldblatt, Helen Bennett Brown
Journal: Journal of Clinical Investigation (1930)

The remarkable power of irradiated ergosterol to prevent or to cure rickets in infants and aimals, first demonstrated for rats by Rosenheim and Webster (1) and Windaus and Hess (2) (3) has been amply con- firmed (4) (5) (6) (7).For rats, 0.000,1 mgm.(8) or less (5) (9) and for infants 2 to 4 mgm.(5) (10) have proved adequate for cure.If such small amounts produce such striking therapeutic results, the question arises, what are the changes brought about by larger doses.The effect of excessive doses was first investigated by Pfannenstiel (11) (12) (13), who found that 4 mgm. of irradiated ergosterol, in the form of Vigantol, administered by mouth daily, caused rapid loss of weight and death of young rabbits fed on a normal diet.Kreitmair and Moll (14) used a great variety and large numbers of animals, and confirmed Pfannenstiel's findings for the rabbit.In addition they (14) found severe pathological calcification in 100 per cent of rats and cats, in 75 per cent of rabbits and mice, in 15 per cent of dogs, and in only one out of 50 guinea-pigs, but observed no effects, following very large doses, in chickens and in axolotl.They did not study the inor- ganic composition of the blood nor the changes that precede these advanced pathological conditions.Their conclusion was that the changes were due to hypervitaminosis and that the calcium deposits were a manifestation of metastatic calcification.The purpose of the present study was to confirm and extend these observations.In addition data were collected to aid in understanding the mechanism by which these changes are brought about.The effect
Wishing you a rational new year
Authors: F. Godlee
Journal: BMJ (2010)

Let’s start the year as we mean to go on—by promoting rational healthcare decisions based on the best available evidence. Des Spence, who has now written a weekly column for the BMJ for four years, ended 2010 with a head-on challenge to paediatric ear, nose, and throat surgeons. He said they were practising bad medicine by continuing to remove tonsils and insert grommets in children’s ears ( BMJ 2010;341:c6560, doi:10.1136/bmj.c6560). In a string of subsequent correspondence, which one contributor says is essential teaching material for registrars (http://bit.ly/i8gkXS), Spence has apologised for offending ENT surgeons and for the sweeping nature of his critique. But he sticks to his guns that these still common procedures do permanent harm and, at most, only …
Investigating Peer Review
Authors: Drummond Rennie
Journal: Annals of Internal Medicine (1988)

Editorials1 August 1988Investigating Peer ReviewDrummond Rennie, MD, Elizabeth Knoll, PhDDrummond Rennie, MDSearch for more papers by this author, Elizabeth Knoll, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-3-181 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAs medicine has grown, it has become clear that no one person could encompass all its expanding fields, and so the twentieth century has been the age of the specialist. Editors of specialty journals are receiving manuscripts of an ever more specialized nature, and increasingly find themselves the only generalists in a field. Their response has invariably been to set up a cadre of expert reviewers who, on this side of the Atlantic, are called peers.Most editors of influential medical journals send manuscripts out to review. Although they are well aware of the system's weaknesses, ranging from delay to...References1. Lock S. A Difficult Balance: Editorial Peer Review in Medicine. London: The Nuffield Provincial Hospitals Trust; 1985. Google Scholar2. Huth E. Guidelines on authorship. Ann Intern Med. 1986;104:269-74. LinkGoogle Scholar3. EnglerCovellFriedmanKitcherPeters RJPPR. Misrepresentation and responsibility in medical research. N Engl J Med. 1987;317:1383-9. CrossrefMedlineGoogle Scholar4. Petersdorf R. The pathogenesis of fraud in medical science. Ann Intern Med. 1986;104:252-4. LinkGoogle Scholar5. Woolf P. Pressure to publish and fraud in science. Ann Intern Med. 1986;104:254-6. LinkGoogle Scholar6. Huth E. Irresponsible authorship and wasteful publication. Ann Intern Med. 1986;104:257-9. LinkGoogle Scholar7. Bailar J. Science, statistics, and deception. Ann Intern Med. 1986;104:259-60. LinkGoogle Scholar8. Angell M. Publish or perish: a proposal. Ann Intern Med. 1986;104:261-2. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Journal of the American Medical Association Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByBiomedical journal speed and efficiency: a cross-sectional pilot survey of author experiencesManuscript Peer Review?A Guide for Health Care ProfessionalsLa revisión por pares en las revistas científicasWho Reviews the Reviewers? Feasibility of Using a Fictitious Manuscript to Evaluate Peer Reviewer Performance 1 August 1988Volume 109, Issue 3Page: 181-181KeywordsPeer review Issue Published: 1 August 1988 PDF DownloadLoading ...
US Senate leader gives support to expanded stem cell research
Authors: Janice Hopkins Tanne
Journal: BMJ (2005)

In a surprising move the leader of the Republican Senate majority, Bill Frist, broke with President Bush last week and said he would support federal funding for research using stem cells from leftover embryos donated by couples who had completed their infertility treatment.

The president had limited federal funds to stem cell lines in existence on 9 August 2001. However, Dr Frist noted, only 22 lines are now available, and they are becoming less stable and may all be contaminated ( BMJ 2005;330: 1285).

Since federal money was not available several states have provided funds for stem cell research. Voters in …
912. Long-Term Efficacy of AAV Vector-Mediated Gene Therapy in the Mouse Model for Glycogen Storage Disease Type la (GSD-Ia)
Authors: Dwight D. Koeberl, Baodong Sun, Tirupapuliyur Damodaran, Talmage Brown, Andrew Bird, Ayn Schneider, David S. Millington, Y.-T. Chen
Journal: Molecular Therapy (2005)

The deficiency of glucose-6-phosphatase (G6Pase) underlies glycogen storage disease type Ia (GSD-Ia, also known as von Gierke disease; MIM 232200), an autosomal recessive disorder of metabolism associated with life-threatening hypoglycemia and growth retardation. Regulation of G6Pase at the level of transcription occurs in response to glucose and insulin levels. The main hypothesis asked whether regulated G6Pase expression with an AAV vector containing a glucose-response promoter would achieve efficacy in GSD-I mice. A secondary hypothesis predicted that efficacy in GSD-Ia would correct the unique gene expression and metabolomic abnormalities of this disorder. An AAV vector containing the glucose-responsive G6Pase promoter driving G6Pase expression (AAV-cG6PGH) was pseudotyped as AAV8 (AAV2/8), and administered intravenously (1 1012 DNAse-resistant vector particles) to 2 week-old affected G6Pase-KO mice (n=7). AAV2/8 vectors previously transduced murine liver >100-fold more efficiently than standard AAV2/2 vectors. Survival was prolonged following AAV vector administration, currently ranging from 3 to 6 months for all treated affected mice, in contrast to untreated affected mice that did not survive past 2-3 weeks of age. Growth was normalized following AAV vector administration, whereas untreated, affected mice initially weighed approximately 50% as much as unaffected littermates and remained growth-retarded. Mice that received the AAV2/8 vector encoding G6Pase had blood glucose in the normal range following 2 hours of fasting (81 +/- 30 mg/dL), in contrast to non-fasting, untreated G6Pase-KO mice, which were hypoglycemic (31 +/- 19 mg/dL) (p < 0.005). It was not necessary to give glucose injections to prolong survival following administration of the AAV2/8 vector, even though affected, untreated mice could only be sustained through twice daily glucose injections. GSD-Ia mice were further characterized to identify outcome measures for gene therapy: gene expression profiling revealed elevated transcripts in the glycolytic, signal transduction, and cell cycle pathways, and metabolomics revealed elevated lactate and ketones in urine of untreated, affected mice. Correction of gene expression profiling and metabolomics in 6 month-old affected mice following AAV vector administration will be analyzed. The efficacy of G6Pase expression with an AAV vector in GSD-Ia has been demonstrated by the correction of fasting hypoglycemia, growth retardation, and disease-specific outcome measures.